MAPT and Alzheimer disease: Although many details surrounding the pathogenesis of Alzheimer’s disease (AD) remain unclear, a dominant viewpoint is that the dysmetabolism of amyloid-β (Aβ) initiates tau pathology that results in neurodegeneration and cognitive decline.